Goldman Sachs says there is a "50% chance of a brief government shutdown" due to President Donald Trump's declining poll ratings. » Read More
Positions won't change based on whether "Goldman Sachs is going to win out over the Klan inside the White House," Josh Brown says. » Read More
By: Tae Kim
Goldman's "Hedge Fund VIP" list is up 19 percent this year through Aug. 14 versus the S&P 500's 12 percent return. » Read More
By: Michael Sheetz
Chicken Soup for Soul Entertainment will begin trading Friday on the Nasdaq under the ticker symbol "CSSE." » Read More
These big winners for the Dow added $92 billion in market value to the pockets of investors, USA Today reports.
Jim Cramer points to a red flag when it comes to retirement.
Jim Cramer offered his guide on how to best prepare for your financial future ahead of the New Year.
Jim Lebenthal, who's up 33 percent this year in his CNBC PRO model portfolio, sells Time Warner.
UBS says UnitedHealth and Amazon are the stocks domestic fund managers are most overweight.
It’s complicated, but one trader makes it simple: He’s betting on pre-inauguration volatility.
Some of the names on the move ahead of the open.
The market rally has nothing to do with Donald Trump's win in the U.S. election in November, an analyst told CNBC Tuesday.
Jim Cramer broke down how to identify a best-of-breed company in a sector.
A Wall Street veteran has hiked his earnings forecast for 2017, citing a more business friendly environment under a Trump administration.
A daily look at the morning's key financial stories.
Jim Cramer opens up about mistakes of investing, and his rules for owning individual stocks.
Carl Icahn shares his market views in an interview with CNBC's Scott Wapner.
Jim Cramer explained how his view of the market was forever rocked by the Great Recession.
One trader said the narrative in retail is that Amazon is outperforming the rest of the sector, but its stock performance doesn't necessarily reflect that.
Wall Street has been hoping to end the year with a bang — with the Dow finishing above 20,000.
Tweeting at Lockheed and Boeing won't necessarily lower defense costs much, but it may give Trump more power, some military analysts say.
The stake would make Alden the top shareholder in the company, according to Thomson Reuters data.
Synergy Pharmaceuticals skyrocketed after the firm reported positive trial results for an irritable bowel syndrome drug.
Jim Cramer drilled down on retail's woes and how the Trump administration could cause further pain to the retail cohort.
Get the best of CNBC in your inbox